All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
2.14 [0.70 ; 6.58 ] Sekine (PLACOVID), 2021 1 0% 160 NA not evaluable death D28detailed results AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Li, 2020 0.59 [0.22; 1.59]
MARIPOSA, 2021 1.43 [0.42; 4.87]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RECOVER, 2021 1.09 [0.38; 3.13]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
0.88 [0.73 ; 1.05 ] AlQahtani, 2020, Aman, 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Jamaati, 2021, Kalil (ACTT-3), 2021, Li, 2020, MARIPOSA, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 23 0% 4,294 moderate low death or transfer to ICUdetailed results Lopardo, 2021 0.65 [0.35; 1.22]
0.65 [0.35 ; 1.22 ] Lopardo, 2021 1 0% 241 NA not evaluable deathsdetailed results AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Cao, 2020 0.15 [0.01; 3.29]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CAPSID, 2021 0.84 [0.28; 2.50]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Li, 2020 0.59 [0.22; 1.59]
Lopardo, 2021 0.57 [0.24; 1.37]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Rasheed, 2020 0.13 [0.01; 1.09]
RECOVER, 2021 1.09 [0.38; 3.13]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.86 [0.76 ; 0.97 ] AlQahtani, 2020, Aman, 2021, Cao, 2020, CAPE-COVID, 2020, CAPSID, 2021, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DEXA-COVID19, 2020, Jamaati, 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RECOVER, 2021, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 39 6% 8,767 moderate critical deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Talaschian, 2021 1.25 [0.30; 5.14]
1.08 [0.83 ; 1.39 ] COVACTA (Rosas), 2020, CP-COVID-19, 2021, Kalil (ACTT-3), 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Talaschian, 2021 6 0% 2,535 moderate serious clinical deteriorationdetailed results Cao, 2020 0.11 [0.01; 2.21]
CAPSID, 2021 0.63 [0.29; 1.40]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
Shu, 2020 0.27 [0.01; 5.58]
0.61 [0.44 ; 0.86 ] Cao, 2020, CAPSID, 2021, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Shu, 2020 5 0% 616 moderate serious clinical improvementdetailed results Cao, 2020 1.67 [0.84; 3.33]
CAPSID, 2021 1.58 [0.71; 3.49]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Li, 2020 1.40 [0.79; 2.49]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 10.27 [1.17; 90.18]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.29 [1.08 ; 1.54 ] Cao, 2020, CAPSID, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (tocilizumab), 2021, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 17 57% 3,883 moderate critical clinical improvement (14-day)detailed results Cao, 2020 2.00 [0.58; 6.94]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
Shu, 2020 10.27 [1.17; 90.18]
1.76 [0.98 ; 3.14 ] Cao, 2020, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, Li, 2020, Shu, 2020 5 60% 1,255 moderate serious clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
1.50 [0.22 ; 10.08 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (28-day)detailed results COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Li, 2020 1.42 [0.65; 3.10]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.32 [0.98 ; 1.77 ] COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 9 33% 1,151 moderate serious clinical improvement (7-day)detailed results Cao, 2020 2.38 [0.38; 14.70]
Li, 2020 0.98 [0.27; 3.58]
Shu, 2020 6.72 [1.50; 30.07]
2.39 [0.73 ; 7.80 ] Cao, 2020, Li, 2020, Shu, 2020 3 45% 185 moderate not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.67 [0.84; 3.33]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
Li, 2020 1.40 [0.79; 2.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
1.17 [1.00 ; 1.36 ] Cao, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020 10 40% 2,323 moderate critical death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Veiga, 2021 1.54 [0.65; 3.63]
0.91 [0.67 ; 1.23 ] CAPE-COVID, 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Rosas (REMDACTA), 2021, Veiga, 2021 4 13% 1,058 moderate not evaluable hospital dischargedetailed results CAPE-COVID, 2020 1.67 [0.87; 3.19]
MARIPOSA, 2021 0.88 [0.55; 1.40]
Rahmani, 2020 3.44 [0.64; 18.49]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
1.09 [0.79 ; 1.49 ] CAPE-COVID, 2020, MARIPOSA, 2021, Rahmani, 2020, Rosas (REMDACTA), 2021 4 38% 864 moderate not evaluable mechanical ventilationdetailed results AlQahtani, 2020 0.67 [0.22; 2.02]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Jamaati, 2021 1.38 [0.45; 4.20]
MARIPOSA, 2021 0.88 [0.37; 2.10]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
Shu, 2020 0.59 [0.02; 14.04]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.85 [0.65 ; 1.12 ] AlQahtani, 2020, CAPE-COVID, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Jamaati, 2021, MARIPOSA, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Tabarsi, 2020 14 0% 1,461 moderate low mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
0.66 [0.25 ; 1.72 ] CP-COVID-19, 2021 1 0% 100 NA not evaluable radiologic improvement (14-day)detailed results Cao, 2020 5.54 [1.01; 30.50]
Jamaati, 2021 4.89 [1.15; 20.79]
Tabarsi, 2020 2.33 [0.45; 12.00]
4.02 [1.61 ; 10.05 ] Cao, 2020, Jamaati, 2021, Tabarsi, 2020 3 0% 175 moderate not evaluable viral clearance detailed results CP-COVID-19, 2021 1.12 [0.16; 7.84]
Raman, 2021 36.42 [10.85; 122.18]
6.97 [0.23 ; 210.35 ] CP-COVID-19, 2021, Raman, 2021 2 89% 200 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Raman, 2021 36.42 [10.85; 122.18]
7.68 [0.34 ; 173.70 ] CP-COVID-19, 2021, Raman, 2021 2 90% 200 moderate not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Lopardo, 2021 0.67 [0.35; 1.28]
Rahmani, 2020 0.37 [0.14; 1.00]
Tabarsi, 2020 0.56 [0.18; 1.74]
0.58 [0.41 ; 0.82 ] COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Lopardo, 2021, Rahmani, 2020, Tabarsi, 2020 7 0% 762 moderate not evaluable recoverydetailed results COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Talaschian, 2021 0.64 [0.14; 2.92]
1.30 [0.64 ; 2.66 ] COV-BARRIER (critically ill), 2022, Talaschian, 2021 2 9% 137 low not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results Cao, 2020 0.11 [0.01; 2.21]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Shi, 2020 1.08 [0.04; 32.96]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.06 [0.85 ; 1.31 ] Cao, 2020, CODEX (Tomazini), 2020, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (plasma), 2021, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Talaschian, 2021, Veiga, 2021 14 33% 4,979 moderate low superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
Rahmani, 2020 0.18 [0.02; 1.59]
0.56 [0.15 ; 2.02 ] CAPE-COVID, 2020, Rahmani, 2020 2 43% 215 low not evaluable adverse eventsdetailed results Cao, 2020 1.60 [0.38; 6.81]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Raman, 2021 1.36 [0.56; 3.30]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shi, 2020 0.88 [0.38; 2.03]
Shu, 2020 2.48 [0.05; 132.54]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Veiga, 2021 1.65 [0.81; 3.37]
1.13 [0.96 ; 1.32 ] Cao, 2020, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Raman, 2021, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Veiga, 2021 12 0% 2,178 moderate low 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 06:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290